Life Sciences Archive » February, 2021

Life Sciences - February, 2021

288 articles

• House Approves Biden's $1.9T Pandemic Relief Package
• DOJ Suffers Rare Rejection Of Late FCA Case Takeover
• 1st Circ. Upholds 3 Ex-NECC Workers' Drug Fraud Convictions
• Arbor Hits FDA With Suit Over Neurological Drug
• Harvest Health Unit Hit With Age, Race Discrimination Suit
• Walgreens Relieved Of Claims It Mislabeled Infant Pain Med
• Bristol Myers, Citigroup Can't Shake NJ Pollution Suit
• Novo Nordisk Hit With Bias Suit Over 'Sexist Work Culture'
• 3rd Circ. Preview: AT&T Leads Packed March Schedule
• Gov't Contracts Of The Month: Vaccines, Post Office Revamp
• 4 Paths The Justices Could Take In Arthrex
• Alleged Chinese Agent At Stanford Denies Obstruction, Fraud
• Cos. Should Back Up Sensory Advertising Claims With Data
• Fla. Bills Seek Cannabis Legalization, Taxation
• Chemours Board Sued In Del. For Undisclosed Toxic Tabs
• FDA Panel Clears J&J COVID-19 Vaccine For Emergency Use
• Baxter Settles Investor Suit Over Forex Accounting Controls
• What Biden's Ethics Pledge Means For Gov't Revolving Door
• March Trial Set For Patent Battle Over Glaucoma Treatment
• UK Litigation Roundup: Here's What You Missed In London
• Meet The Supreme Court Heavyweights Arguing Arthrex
• Investors Maintain Nerve Repair Co. Axogen Lied In SEC Docs
• Small Odds Humira Patents All Invalid 'Worries' 7th Circ
• Mallinckrodt Wins Tussle Over Ch. 11 Deadline Extension
• Judge Refuses To End Sterigenics' Suit Against Ga. County
• Tribunal Upholds CMA's Antidepressant Market Rigging Fine
• Sparks Fly As Sen. Committee Mulls Top Biden Health Picks
• Insurers Can't Be Charged For Medical Pot, Mass. Court Says
• Punishing Bar Exam Policies On Menstrual Products Must Go
• The Supreme Court PTAB Cases That Came Before Arthrex
• Cell-Based Drugmaker Cellarity Nabs $123M From Investors
• Deals Rumor Mill: Toast, Sportradar, Victoria's Secret
• Covington, Skadden Rep Merck's $1.9B Pandion Buy
• As McKinsey Is Dragged Into MDL, Fresh Atty Tensions Arise
• Rosen to Rep Biogen Investors In Drug Trial Fraud Suit
• Nevro Lobs New Suit At Boston Scientific Over Spine Pain IP
• Justices Urged To Fix Fed. Circ. 'Paradox' In Heart Drug Case
• Two Mo. Pot Cos. Win Licenses In Appeal Over Scoring Flaws
• Takeaways From DOJ Fraud Section's Pandemic Year
• Rakoff Hits Ex-MiMedx Exec With 1 Year For Fraud Scheme
• Medtronic Recalls Stent System After Trial Patient Death
• Moderna Asks Fed. Circ. To Undo Drug-Delivery Patent Ruling
• EPA Hazardous Pharma Waste Rule Has Wide Reach
• Zofran Birth Defect MDL Finally Heading For Trial In Fall
• It's Time For Law Firms To Start Loving And Leveraging Data
• Cahill Gordon, Paul Weiss Shape $12B ICON-PRA Health Deal
• Biden Orders Sweeping Review Of Crucial Supply Chains
• Should An Atty Lead HHS? Lawmakers Debate Pros And Cons
• Unaddressed Split On FCA Objectivity May Spur Settlements
• Illumina Wants 'Entirely Derivative' Antitrust Suit Paused
• Fed. Circ. Tailors Arguments After Teva Skinny Label Outcry
• Justices Told Assignor Estoppel Is 'Uncommonly Lawless'
• 7th Circ. To Crawl Into Humira 'Patent Thicket' Dispute
• Unrepentant Ex-MiMedx CEO Gets 1 Year For Revenue Fraud
• Keys To Protecting Clients During Law Firm Dissolution
• AdventHealth's Fraud Claim Over $57M PPE Deal Advanced
• Pa. Public Housing Agency Must Create Medical Pot Policy
• Coronavirus Regulations: A State-By-State Week In Review
• 10th Circ. Ruling Bolsters Medical Device Preemption Defense
• J&J Reserves $4B For Talc Verdict, Expenses
• Del. Justices Reverse Express Scripts' $82M Trial Loss
• Wife Can't Blame Husband's Co. For Her COVID-19 Infection
• 3 Developments As America's Virus Death Toll Hits 500,000
• Walmart Says DOJ's 'Sensationalist' Opioid Suit Rings Hollow
• Atty Contests Legal Lender's Entry In $350M Shire Fee Row
• Mallinckrodt Ch. 11 Plan Lacks Support For Now, Lenders Say
• Va. Corrections Dept. Can't Escape Body Scan Sex-Bias Suit
• EPA Takes Action To Address PFAS In Drinking Water
• Allergan Patents Spared From PTAB Review In Settlement
• NY AG Opioid Trial Gets March Start After COVID-19 Delays
• SD Pot Advocates Pitch Compromise Medical Marijuana Bill
• How Case Management Orders Can Support New Attorneys
• Justices Reject FCA Liability Requirement Case
• High Court Ruling May Be A Boon For Benefits Access
• Biden Stacking Health Team With Vets Of BigLaw, AG Offices
• Companies Beef Up Risk Disclosures As Biden Era Begins
• EU Clears Varian's $16.4B Sale To Siemens Unit With Fixes
• Baby Formula Device Claims Get Tossed By NY Federal Judge
• 3 Things To Know About FDA's Evolving Drug Inspections
• WB Mason 'Preyed' On Buyers With Fake 3M Masks, Suit Says
• Botox Rival Can Stay On Market Following Allergan Deal
• Health Hires: Hogan Lovells, McGuireWoods
• 2 Firms Tapped To Lead Teva Intrauterine Device MDL
• Bleichmar Fonti Wants To Retake Lead In Endo Investor Suit
• Courts, FTC May Differ On Sponsored Product Reviews
• An In-House Counsel's Guide To Better Work Management
• UK Litigation Roundup: Here's What You Missed In London
• Bayer's $650M PCB Deal Hits Snag Over Extra Funds Window
• Calif. Appeals Court Upholds Judgment In Nerve Damage Case
• NJ Lab Sues Supplier Over False COVID-19 Test Results
• NJ Medical Pot Hopefuls Lose Challenge Over Technical Woes
• 'Opioid Baby' Claims Better Suited For Own Cases, Attys Say
• Mallinckrodt Says Competitor Unlawfully Recruited Employees
• Biologics Face Tougher Patent Scrutiny After Amgen Ruling
• Coronavirus Litigation: The Week In Review
• Drug Database Provider Wins Challenge To OTC Label Change
• Fed. Circ. Says PTAB Wrongly Upheld Cancer Detection Patent
• Genetic Engineering And The Endangered Species Act
• Energy Distributor Sells Chemicals Biz To PE Firm For $570M
• US Cos. Must Prepare For EU Carbon Tax On Imports
• Minn. Cannabis Legalization, Tax Bill Passes House Panel
• How The Pandemic Is Shaping Patent Trials In District Courts
• Justices Should Weigh In On FCA Objective Falsity Standard
• Avoiding Materially Adverse Conflicts After New ABA Opinion
• Deals Rumor Mill: SpaceX, Marqeta, Aerion
• ViSalus Can't Get Trial Redo In $925M Robocall Suit
• Fee Award Reversed In Fla. Medical Marijuana Rule Challenge
• OptumRx Worker Says Turning Down Exec Hurt Her Career
• HHS Assails Eli Lilly's Bid To Halt Drug Discount Rule
• Ex-Theranos CEO Holmes Pans 'Luxurious Lifestyle' Evidence
• Sackler Family Can't Keep Names Of Its Businesses Secret
• Sport Supplement Exec Gets 1 Year For Illicit Steroid Sales
• Coronavirus Regulations: A State-By-State Week In Review
• McKesson Whistleblowers' Opioid FCA Suit Sunk By Escobar
• Stimwave Founder Can't Get Rethink Of Legal Fee Denial
• Inovio Must Face Trimmed Investor Claims Over Virus Vaccine
• McKinsey's Opioid Woes Far From Over Despite $600M Deals
• Parents Ask Judge To Rethink Cert. Denial For 'Opioid Babies'
• Fed. Circ. Grants Last-Minute Pause Of ITC's Botox Rival Ban
• Full Fed. Circ. Won't Rethink Ruling UT Isn't Immune From IPR
• Bristol Myers, Sanofi To Appeal $834M Hawaii Order On Plavix
• Fed. Circ. Won't Revive Generics' Bid To Ax Takeda Patent
• Ex-Vitamin Shoppe CFO Sues For At Least $1.4M In Benefits
• Biomet Seeks Judgment, New Trial In $3.5M Implant Suit
• US Legal System Can Benefit From Nonlawyer Ownership
• FDA Hammers Drugmaker's 'Dangerous' Opioid Promos
• Curaleaf Beats Investors' Stock-Drop Suit Over CBD Legality
• Robbins Geller To Lead Sorrento COVID-19 Class Action
• BMS Accuses Teva Of Infringing Eliquis Blood Thinner Patent
• Royal Mail Settles Antitrust Suit With Medical Testing Co.
• 7 False Claims Act Enforcement Trends To Watch
• Untimely Claims Trimmed From Mich. Medical Pot Raid Suit
• Sandoz Tells Justices Amgen Ruling 'Guts' Patent System
• What Life Sci Attys Think Of Biden's Pace Choosing FDA Boss
• CBD Co. Says Rival Unlawfully Using Its Own Trademark
• Judge Tosses Suit Over Pot Testing Machines
• China Asks 2nd Circ. To Argue For Vitamin C Exporters Again
• Cannabis Bill Roundup: Battle Over SD Medical Takes Shape
• Shoe Insert Co. Accuses Rival Of Bad-Mouthing It In Emails
• Robbins Geller's Money Experts Clinch $1.2B Valeant Deal
• Fed. Circ. Judge 'Baffled' By Mylan Position In PTAB Appeal
• Sorin Group Granted Win In Heart Valve Death Suit
• Pa. Water Utility Says DuPont Illegally Transferred PFAS Biz
• 3 Drug Pricing Strategy Considerations Under Biden Admin.
• Key Deliverables For SPAC Parties Amid Growth Trend
• FDA Warns 11 E-Cig Sellers Over Unauthorized Products
• Risk Allocation For Drug And Device Cos. And Their Suppliers
• UK Litigation Roundup: Here's What You Missed In London
• Gilead, Bristol-Myers Say Direct Buyers Antitrust Suit Too Late
• US Pays Pfizer, Moderna $3.7B For 200M More Vaccine Doses
• Fed. Circ. Says Amgen's Repatha Patents Are Too Expansive
• ADHD Drug Buyer May Need To Arbitrate Antitrust Claims
• Coronavirus Litigation: The Week In Review
• Calif. Man Can't Recover Confiscated Pot, Despite Court Order
• PTAB Grills Mylan And Merck In Diabetes Drug IP Battle
• Miss. Mayor Says Advocate Can't Argue For Medical Pot
• Calif. Biotech Firm Settles SEC's COVID-19 Blood Test Claims
• Merck Sues To Block Inventia's Generic Diabetes Drug
• GAO Says Drug Test Deal Debrief Can't Extend Protest Period
• Building A Law Firm Knowledge Bank For Thought Leadership
• Blue Cross Units, CVS Want Drug Pricing Suits Combined
• What The Biden Presidency Means For Class Actions
• Del. Justices Affirm AstraZeneca Win In Lifted-Data Suit
• Cannabis Co. Insurer Says Faulty Pump Caused $1.5M Fire
• Medtronic Skirted Spine Device FDA Review, 9th Circ. Told
• GAO Signs Off On VA's Medical Supply Contract Awards
• Teva 'Not Optimistic' About Sealing $23B Opioid Deal Soon
• 7th Circ. Asked To Revive Safeway Drug Price Suit
• FDA Warns Mexican Co. Over Hand Sanitizer Strength
• Tribes Insist On Hand In Mallinckrodt Ch. 11 Mediation
• J&J Seeks To Block Alcon's Eye Surgery Laser Product
• PTAB Wipes Out Rembrandt's Drug Testing Patent On Remand
• Data Compliance Issues For Cos. Making, Using Vaccine Apps
• Genentech Wins Toss Of Employee's 401(k) Suit
• Blank-Check Merger Values Genomic, Patient Data Biz At $2B
• Let's Emerge From The Pandemic As Legal Innovators
• SD Gov. Noem To Delay Medical Pot Rollout By A Year
• Indivior Investor Wants OK For $2M Deal In Suboxone Dispute
• EU Accepts Aspen Offer To Slash Prices On Cancer Drugs
• Greenberg Traurig Adds Top Becton Dickinson Atty In NJ
• Teva-Centric Price-Fix Case Likely To Lose Bellwether Status
• AbbVie, Others Move To End Generic Bystolic Antitrust Claims
• Pfizer Says It's Immune From Vaccine Testing IP Claims
• 3rd Circ. Won't Give Fresenius Another Look At Drug Claim
• Fresenius To Pay $50M For Impeding FDA Investigation
• Celgene Sues Dr. Reddy's To Block Cancer Drug Generic
• Kirkland, Wilson Sonsini Guide Deal Forming $1.3B Biotech
• Abbott Labs Ducks Ex-Worker's ERISA Suit Over Stolen $245K
• Ex-Theranos COO's Fraud Trial Moved To January 2022
• Texas Atty Arrested On Telephone Harassment Charge
• Ex-Client Fights To Revive Botched IUD Malpractice Case
• Coronavirus Regulations: A State-By-State Week In Review
• Anticipating Predictive Analytics' Potential Uses In Litigation
• Fed. Circ. Panel Walks Back $235M Skinny Label Ruling
• Novelion Therapeutics Seeks Ch. 15 To Wind Up Liquidation
• Catalent Hit With Patent Suit Over Epilepsy Drug Vimpat
• ​​​​​​​One Of Trump Admin.'s Top Health Attys Talks Enforcement
• Bumble Upsizes IPO As More Companies Join Pipeline
• Dechert Picks Up IP Partner From Lathrop
• Winston & Strawn Hires Appellate Partner For DC Office
• Whistleblower Gets $3.6M In FCA Deal With Roche, Humana
• Claim Clipped From Cardinal Investors' Suit Over Opioids
• 8th Circ. Won't Revive Suit Over Teva's ParaGard Risks
• Biotech Consultant Hit With Insider Trading Charges
• This Black History Month, Law Firms Should Challenge Norms
• Del. Justices Reject Meso's Bouchard-Related Bias Claims
• Baker Botts Lands Bankruptcy Pro From Greenberg Traurig
• CEO Ken Frazier, Once GC, To Retire From Merck
• Astellas Gets Scientists Cut From Stem Cell Patent After Trial
• Judge Says Inventors Would 'Radically Alter' Tech's PTAB Suit
• 5th Circ. Won't Revive Claims Tying Generic Drugs To Disease
• Fla. Biz Owner Pleads Out Of $400M Health Fraud Case
• Lead Plaintiff Booted From Endo Suit Over 97-Second Lag
• J&J Wins Settlement In Counterfeit Device Row
• Acthar Claimants Hit Skadden For Mallinckrodt Ch. 11 Role
• Bipartisan Senate Bill To Spur Marijuana Research Is Back
• Cannabis Bill Roundup: Va. On Track To OK Recreational Pot
• Exec Says Johnson & Johnson Cut His Job After Surgery
• 9th Circ. Won't Revive Breast Implant Suits Against J&J Unit
• Key FCA Developments From 2020 And What To Expect Next
• A Look At Factors Influencing Medical Device Approval Speed
• Fresenius Lost Chance To Appeal Antitrust Suit, 3rd Circ. Told
• Goodwin-Led Gene Therapy Co. Nabs $150M Via PIPE
• Health Hires: GrayRobinson, MiraMed, AngioDynamics
• Judges On Race
• Law Firm Penalties On Departing Partners Just Got Riskier
• Walmart Loses Bid To Short-Circuit Feds' Opioid Suit
• J&J Seeks Emergency Approval For 1-Shot COVID-19 Vaccine
• McKinsey Deal Renews Friction Among AGs And Opioid Attys
• Bayer's $2B Deal May Not Spell The End For Roundup
• No Thanks, EpiPen Buyers Tell Judge After Trial Delay Invite
• Coronavirus Litigation: The Week In Review
• Coalition Says Bayh-Dole Not For Cutting Drug Costs
• Sana's Smash IPO Tops Biotech Trio Raising $811M Combined
• Period App Shared Health Data With Advertisers, User Says
• CytoDyn Panel Seeks To Reverse $14M Directors Award
• Former Patients Say Rockefeller U. Knew About Sex Abuse
• Litigation Funder Wants Cut Of $350M Shire Deal
• Keller Lenkner Hires Former Aide To Texas AG, White House
• More Senior Staff Accuse UnitedHealth Unit Of No-Poach Plot
• NJ Case Has Lessons On Arbitration Clauses In Atty Retainers
• McKinsey To Pay $573M To Settle Opioid Marketing Claims
• Former Fla. Professor Charged With Fraud, Hiding China Ties
• Covidien Tells Panel That Judge Garbled Patent Case Verdict
• Dollar General Inks $1.8M Deal In Infant Drug False Ad Suit
• Challenging Therapeutics IP After Fed. Circ. Drink Can Ruling
• Biotech Co. Can't Hide DNA Program Info In NJ Murder Case
• Coughlin Duffy Group Jumps To Schenck Price
• Tips For Protecting Privilege When Working With Outside PR
• Senate Panel OKs Commerce Nominee Despite Huawei Doubts
• 3 Procurement Priorities For Law Firms In Uncertain Times
• Bayer Inks $2B Deal To Cover Future Roundup Cancer Claims
• Teva Aims To Revoke IP For BMS Blockbuster Blood Thinner
• 5 Firms Aid As Jazz Pays $7.2B For Rare Disease Drugmaker
• Par Pharma Abusing FDA Process To Foil Rivals, Amneal Says
• Quest Diagnostics Defeats Fired Worker's Disability Bias Suit
• SEC Nabs Partial Win Against Ex-Biotech Executives
• Humira Buyers Say AbbVie 'Contorting' Actavis At 7th Circ.
• Final OK On $1.2B Valeant Deal Earns Robbins Geller $157M
• Investors Seek Class Cert. In Humira Marketing Suit
• NewLink Inks $13.5M Deal In Investor Suit Over Cancer Drug
• Structuring Protein-Specific Life Science Partnerships
• Okla. Worker Fired For THC Test Can't Claim Discrimination
• NJ Court Wary Of Medical Pot Hopefuls' Claims Of Tech Glitch
• FDA Warns Sites Over Malaria Drug COVID-19 Claims
• 4th Circ. Revives Bayer's Yearslong 'Flanax' Trademark Fight
• Coronavirus Regulations: A State-By-State Week In Review
• Examining EPO's Strict Approach To AI Patent Disclosure
• UK Is Proof Nonlawyer Ownership Threatens Legal Profession
• Minn. Bill Seeks To Legalize, Tax Recreational Marijuana
• Judge Invalidates Changes To NM Medical Cannabis Rules
• Fed. Circ. Affirms Illumina PTAB Wins Axing Columbia DNA IP
• Consulting Co. McKinsey Sued For Promoting OxyContin
• PhRMA Slams 'Extreme' Call To Strip COVID-19 Patents
• CBD Industry Awaits Action From New Dem-Led Congress
• 'Opioid Babies' Can't Get Class Certification In MDL
• Idaho Lawmakers Push To Make Legal Pot Unconstitutional
• HIG Seeks To Bar Refiling Of False Claims Act Case
• GSK Blasts Teva's Rehearing Bid In $235M Verdict Fight
• Purdue Sues In Ch. 11 To Access $3.3B Insurance Funds
• Blitz Of Biotechs Join Crowded IPO Lineup To Start February
• Bio-Rad's $35M IP Win Tainted By Falsehoods, 10X Says
• Microsoft Can't Apportion Sales Tax, Mass. Justices Told
• FDA Says 30 Websites Shuttered Over Illegal Opioid Sales
• Feds Agree To Push Back Drug Rebate Rule
• Remote Bar Exams Pose New Learning Disability Challenges
• WTO Leaders Call For Unity, Relaxed Vaccine Restrictions
• Cooley, Mintz Levin Craft $3.05B Deal For Drug Developer